Moderna (MRNA) stock has soared in the triple digits this year, outpacing AI players such as Nvidia and Micron Technology on investor interest in its mRNA platform and oncology pipeline. Its personalized cancer vaccine, intismeran autogene, is in 10 clinical trials, including a phase 3 melanoma study combined with Merck’s Keytruda, and preliminary August results sent the stock up 177% in one session. A recent data leak from that trial pushed the stock lower, but the full release confirmed the August results, and some investors may have sold to realize gains. Moderna reports third-quarter earnings on Nov. 6, after reiterating that revenue could grow as much as 10% this year, and investors will also watch its flu vaccine launched last month. The author does not expect the stock to soar right after the report, and instead sees the next potential leg up coming ahead of fresh data or a milestone on the personalized cancer vaccine.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Modernapharmaceuticalsvaccinesearnings
Open a keyword to see other news on the same topic.
Related news
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
Biotech news this week focuses on kidney cancer, multiple sclerosis, Huntington's disease and personalized cancer treatment, as Arcus Biosciences (RCUS), Alnylam (ALNY), Moderna (MRNA) and Merck (MRK) release clinical updates alongside earnings and conferences. Last week, the health care ETF XLV gained 3%, outperforming SPY (down 2%) and QQQ (down 6%), while the biotech ETF XBI fell 6%. Arcus will present kidney-cancer data from its ARC-20 study of Casdatifan, Achieve Life Sciences will report year-long Cytisinicline findings for smoking cessation after a June FDA rejection it says concerned manufacturing and labeling, and Alnylam will share initial Phase 1 ALN-HTT02 results for Huntington's disease. Moderna and Merck will present Phase 3 INTerpath-001 melanoma data on Saturday, comparing individualized treatment intismeran autogene plus Keytruda with Keytruda alone after surgery, while a number of other companies will present multiple sclerosis updates through the week.
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
Moderna shares fell 7% to $185.74 in morning trading after its personalized melanoma vaccine, intismeran autogene, given with Keytruda, met its primary goal of reducing the risk of recurrence or death, but its effect on distant metastasis was far smaller than an earlier mid-stage study suggested. Detailed late-stage results were released on October 22 ahead of a conference in Madrid. BioNTech fell 3% to $85.65, Merck fell 0.2% to $145.61 and Pfizer fell 0.2% to $29.96, while the iShares Biotechnology ETF rose 0.2% to $208.21. The article notes Moderna's business relies entirely on mRNA medicines, so the vaccine carries a large share of its pipeline value, and says the next step is whether the full dataset supports a regulatory filing.
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction
Six melanoma specialists told CNBC that Phase 3 results for Moderna and Merck's personalized cancer vaccine, intismeran autogene, given with Keytruda represent a clinically meaningful advance. The combination reduced the risk of melanoma recurrence or death by 42% and the risk of distant spread or death by 38% compared with Keytruda alone, in a trial of roughly 1,100 patients whose tumors were surgically removed. Doctors said it could eventually become a standard of care for patients who have surgery first and have not received immunotherapy beforehand, though questions remain about survival benefit and which patients benefit most. Moderna shares fell as much as 25% on Thursday after partial data leaked on social media, even though the stock is up nearly 600% this year on optimism about the cancer shot. Moderna is finishing a regulatory filing and aims to get the drug fully approved next year.
Related markets
Latest news
- Restaurant Brands reports mixed results as Burger King's U.S. turnaround shows signs of success
Restaurant Brands International reported mixed third-quarter fiscal results: adjusted earnings of $1.10 per share beat the $1.09 expected, while revenue of $2.53 billion came in slightly below the $2.54 billion analysts expected. Net revenue rose 3.1%, and same-store sales grew 3.8% across all restaurants. Burger King was the top performer, with U.S. same-store sales up 8.4% as its home market undergoes a multiyear turnaround. Popeyes was the laggard, with U.S. same-store sales down 2.2% as rival chicken chains lured customers away with discounts. Tim Hortons posted 1.8% same-store growth in Canada, and international same-store sales rose 3.9%, fueled by Burger King locations.
- Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck beat third-quarter estimates, reporting adjusted earnings of $2.49 per share versus $2.08 expected and revenue of $18.09 billion, up 5% from a year earlier. The company raised its full-year adjusted earnings outlook to $2.77–$2.82 per share from $2.66–$2.76, although the guidance now includes a one-time $400 million charge, or 12 cents per share, tied to a licensing agreement with Chinese cancer drugmaker SciBrunch. Keytruda sales reached $8.60 billion, above the $7.73 billion analysts expected, including $830 million from the injectable Keytruda Qlex versus $649 million expected. Merck is moving patients from the intravenous Keytruda to Qlex to defend market share as key Keytruda patents begin expiring in 2028. Winrevair sales rose 93% to $694 million, and Gardasil drew about $2 billion on higher U.S. demand.
- Zacatecas Silver Receives Drill Permit and Finalizes Maiden Drill Program at Oso Negro, Sonora
Zacatecas Silver (TSXV: ZAC) has received the drill permit from SEMARNAT for its Oso Negro gold-silver concession in Sonora, Mexico, completing the final regulatory requirement before drilling. The company has finalized a 2,500-metre maiden diamond drill program across the Prospecto and Tere vein systems, collared from 20 pads with shallow angled holes designed to intersect veins 40 to 80 vertical metres below high-grade rock chip outcrops. The project lies entirely on private land, where surface access is secured under an initial one-year term that is renewable. Rock chip sampling across more than 3 kilometres of mapped vein strike returned assays up to 20.3 g/t gold and 3,480 g/t silver from 510 samples.
- Luca Intersects 19 Metres of 6.3 g/t Gold Equivalent from the Creston Vein at Tahuehueto Mine
Luca Mining (TSXV: LUCA) reported new assay results from its 2026 exploration drilling at the Tahuehueto gold-silver mine in Durango, Mexico. The standout hole, TRT26-15, cut 18.7 metres of 6.28 g/t gold equivalent in the Creston Vein, wider and higher-grade than the resource model anticipated. The intersection sits near existing underground infrastructure and within an area scheduled for mining in the first half of 2027, and could add high-grade mill feed in the near term. Drilling at the Catorce and Santiago veins also returned high-grade intervals, including 13.7 metres of 3.33 g/t AuEq at Catorce and 11.6 metres of 5.21 g/t AuEq at Santiago, supporting potential resource expansion near the mine.
- NorthWest Intersects 73.9 Metres Of 1.39% CuEq, 0.51% Copper and 0.79 G/T Gold From 457 Metres, Expanding The Western Zone At Kwanika
NorthWest Copper (TSX-V: NWST) reported additional copper-gold assays from the Western Zone of its 100%-owned Kwanika project in British Columbia, highlighted by 73.9 metres grading 1.39% copper equivalent, including 25.9 metres at 2.19% CuEq anchored by 1.58 g/t gold. The three holes come from the completed 43-hole, 12,291-metre 2026 program and extended higher-grade mineralization about 50 metres up-dip while closing a geological gap in Unit 2 near current resources. Drilling below the resource also intersected primary copper-gold porphyry mineralization enriched in palladium, plus a broad low-grade structure at depth. Drill spacing was reduced to about 50 metres in targeted areas to support upgraded Indicated resources, and results from 26 remaining holes in the North Pit Extension Zone are still pending.
- FPT Retail Posts VND 48,273 Billion in Revenue After Nine Months, Up 33% Year-on-Year
In the first nine months of 2026, FPT Retail (HoSE: FRT) recorded consolidated revenue of VND 48,273 billion, up 33% year-on-year, and pre-tax profit of VND 1,724 billion, up 114%. Company-wide online revenue reached VND 8,283 billion, up 29%, while consolidated revenue in the third quarter alone rose 34%. The Long Châu chain generated VND 33,408 billion, up 35% and accounting for 69% of consolidated revenue, and now operates 2,741 pharmacies and 244 vaccination centres after adding 324 pharmacies and 21 vaccination centres since the start of the year. FPT Shop posted revenue of VND 15,014 billion, up 30%, with 622 stores nationwide.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.